ClinicalTrials.gg
CompletedNCT04575467Updated Aug 9, 2024Results posted

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

A Phase 2 interventional study of CBL-514 in Subcutaneous Fat, sponsored by Caliway Biopharmaceuticals Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Caliway Biopharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study. The primary objectives are to evaluate the safety and tolerability of injection lipolysis with CBL-514. It will be followed by a parallel-arm multiple-dose design in Stage 2.

02

Conditions studied

  • Subcutaneous Fat
03

In context

Lead sponsor

Caliway Biopharmaceuticals Co., Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) >18.5 and \<32 kg/m2 and body weight ≥50 kg at Screening and Day 1.
  2. Subject has sufficient thigh subcutaneous fat thickness of at least 1.50 cm (15.0 mm) and up to 5.00 cm (50.0 mm) measured by ultrasound, surrounding the center of treatment area at Screening and Day 1.
  3. Subject has stable body weight (identified as ≤ 5% weight change) for at least 3 months before Screening and during the study.
  4. Subject who has maintained a stable lifestyle (e.g. exercise, eating patterns, and smoking habit) for at least 3 months before Screening and during the study.
  5. Voluntarily signs the Form (ICF) and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Female subject of who is not willing to commit to an acceptable regimen with her partner from the time of Screening and throughout study participation until 90 days after the last product (IP) dose, or who is currently pregnant or lactating. Male subject who is not willing to commit to an acceptable contraceptive method.

    Females who have been surgically sterilized (hysterectomy or bilateral oophorectomy) or who are (e.g., defined as at least 50 years with ≥12 months of amenorrhea with a follicle stimulating hormone (FSH) >40 IU/L) are considered to be of non-childbearing potential. Subjects who are not of childbearing potential are not required to use contraception.

  2. Subject diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede coagulation or aggregation.
  3. Subject has fasting (HbA1c) ≥ 9%, delayed would healing, or any diabetic risks which, in the opinion of Investigator, is inappropriate to participate in the study.
  4. Subject has a cardiovascular disease and abnormal findings in (ECG).
  5. Subject with active or prior history of within 5 years before Screening or being worked-up for a possible malignancy. Except adequately treated basal cell carcinoma of skin and in situ squamous cell carcinoma of skin would be eligible as per Investigator's discretion.
  6. Subject with a history of (HIV)-1, infection or subjects with active HIV infection at Screening with positive HIV antigen/antibody (Ag/Ab) combo test.
  7. Subjects with any hepatic medical condition that would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or provide .
  8. Subject has abnormal skin or local skin conditions at the treatment area, which in the opinion of Investigator, is inappropriate to participate in the study, including but not limited to any of the following:

    1. Skin manifestations of a systemic disease,
    2. Any abnormality of the skin or soft tissues of the area to be treated,
    3. Grade III cellulite (Nürnberger and Muller scale, Nürnberger F, 1978) at the area to be treated,
    4. Skin folding on treatment area when the subject is in the supine position,
    5. Sensory loss or dysesthesia in the area to be treated,
    6. Evidence of any cause of enlargement in the area to be treated other than localized subcutaneous fat,
    7. Tattoos on the area to be treated.
  9. Subject who has undergone the following procedures:

    1. Previous surgery in the anticipated treatment area,
    2. Cardiac pacemakers or any implantable electrical device,
    3. Metal implants of any type in the area to be treated,
    4. Esthetic procedure i.e. liposuction to the region to be treated,
    5. Esthetic procedure e.g. cryolipolysis, ultrasonic lipolysis, low level laser therapy (LLLT), lipolysis injection to the region to be treated within 12 months before Screening or during the study.
  10. Subject is on prescription or over-the-counter (OTC) weight reduction medication or weight reduction programs within 3 months before Screening or during the study.
  11. Subject is undergoing chronic or therapy.
  12. Requiring continual use of the following therapeutic agents during the study: S mephenytoin (Mesantoin), terfenadine (Teldane), buspirone (Buspar), fexofenadine (Fexotabs, Tefodine, Telfast, Xergic, Allegra, etc.).

    If a subject needs to use the above mentioned therapeutic agents during the study for any reason, these therapeutic agents should not be used at least for 48 hours prior to dosing and until 24 hours post-dose.

  13. Unable to receive topical anesthesia (e.g., history of to Benzocaine, lidocaine, or Tetracaine).
  14. Subjects with known allergies or sensitivities to the IP or its components.
  15. Subjects with inadequate liver function at Screening defined as (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALKP), total (TBIL), or gamma-glutamyl transferase (GGT) >3.0 × (ULN).
  16. Subjects with inadequate renal function, defined as abnormal serum creatinine, and urea >1.5 × ULN or estimated (eGFR) \<60 mL/min/1.73 m2. Subjects who are currently on dialysis should be excluded.
  17. Use of other investigational drug or device within 4 weeks prior to Screening
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    CBL-514 320 mg

    CBL-514 will be administered via injection into the thigh subcutaneous adipose layer.

    Drug: CBL-514

  • Experimental
    CBL-514 480 mg

    CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.

    Drug: CBL-514

  • Experimental
    CBL-514 640 mg

    CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.

    Drug: CBL-514

  • Experimental
    CBL-514 800 mg

    CBL-514 will be administered via injection into the abdomen subcutaneous adipose layer.

    Drug: CBL-514

Interventions

  • CBL-514 will be administered via injection into the subcutaneous adipose layer.

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events

    Number of treatment emergent adverse events (TEAEs)

    Time frame: Up to 4 weeks after treatment

  2. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

    The clinical laboratory tests include Biochemistry, Hematology, Coagulation and Urinalysis test

    Time frame: Up to 4 weeks after treatment

  3. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital signs measurements include temperature, pulse rate, blood pressure, and respiratory rate

    Time frame: Up to 4 weeks after treatment

  4. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

    ECG parameters include heart rate, RR interval, PR interval, QT interval, QTc interval, and QRS interval

    Time frame: Up to 4 weeks after treatment

  5. Number of Participants With Clinically Significant Abnormalities in Physical Examination

    Physical examinations include assessment of cardiovascular, respiratory, gastrointestinal, and neurological systems

    Time frame: Up to 4 weeks after treatment

  6. Number of Participants With Injection Site Reactions

    Injection site reactions include but not limited to redness, swelling, bruising, tenderness, itching, pain, warmth, discoloration and hardness

    Time frame: Up to 4 weeks after treatment

Secondary outcomes

  1. Change in Subcutaneous Fat Thickness

    Change in subcutaneous fat thickness as measured by ultrasound compared to Baseline. No efficacy assessments were done for Group 1 of Stage 1 study.

    Time frame: Up to 4 weeks after treatment

  2. Change in Subcutaneous Fat Volume

    Change in subcutaneous fat volume over the treated area as measured by ultrasound compared to Baseline. No efficacy assessments were done for Group 1 of Stage 1 study.

    Time frame: Up to 4 weeks after treatment

07

Results

Posted Mar 28, 2024

Participant flow

Participant flow — Overall Study
MilestoneCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Started6766
Completed6666
Not completed0100
Withdrew: Adverse event0100

Outcome measures

PrimaryNumber of Treatment Emergent Adverse Events

Number of treatment emergent adverse events (TEAEs)

Time frame:
Up to 4 weeks after treatment
Reported as:
Number · number of events
Number of Treatment Emergent Adverse Events
number of eventsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Treatment Emergent Adverse Events103576961
PrimaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

The clinical laboratory tests include Biochemistry, Hematology, Coagulation and Urinalysis test

Time frame:
Up to 4 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
ParticipantsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values0001
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs measurements include temperature, pulse rate, blood pressure, and respiratory rate

Time frame:
Up to 4 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Participants With Clinically Significant Abnormalities in Vital Signs0000
PrimaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)

ECG parameters include heart rate, RR interval, PR interval, QT interval, QTc interval, and QRS interval

Time frame:
Up to 4 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
ParticipantsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)0000
PrimaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination

Physical examinations include assessment of cardiovascular, respiratory, gastrointestinal, and neurological systems

Time frame:
Up to 4 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination
ParticipantsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Participants With Clinically Significant Abnormalities in Physical Examination0000
PrimaryNumber of Participants With Injection Site Reactions

Injection site reactions include but not limited to redness, swelling, bruising, tenderness, itching, pain, warmth, discoloration and hardness

Time frame:
Up to 4 weeks after treatment
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions
ParticipantsCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Number of Participants With Injection Site Reactions6766
SecondaryChange in Subcutaneous Fat Thickness

Change in subcutaneous fat thickness as measured by ultrasound compared to Baseline. No efficacy assessments were done for Group 1 of Stage 1 study.

Time frame:
Up to 4 weeks after treatment
Reported as:
Mean · Absolute Change (mm) from Baseline
Change in Subcutaneous Fat Thickness
Absolute Change (mm) from BaselineCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Change in Subcutaneous Fat Thickness-4.77 ± 2.29-4.85 ± 2.02-2.98 ± 2.83
Statistical analysis
  • CBL-514 480 mg · Paired t-test · p = <0.01 · Mean absolute fat thickness difference: -4.77 · 95% CI -7.17 to -2.37
  • CBL-514 640 mg · Paired t-test · p = <0.01 · Mean absolute fat thickness difference: -4.85 · 95% CI -6.97 to -2.73
  • CBL-514 800 mg · Paired t-test · p = <0.05 · Mean absolute fat thickness difference: -2.98 · 95% CI -5.95 to -0.01
SecondaryChange in Subcutaneous Fat Volume

Change in subcutaneous fat volume over the treated area as measured by ultrasound compared to Baseline. No efficacy assessments were done for Group 1 of Stage 1 study.

Time frame:
Up to 4 weeks after treatment
Reported as:
Mean · Absolute change (mL) from Baseline
Change in Subcutaneous Fat Volume
Absolute change (mL) from BaselineCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Change in Subcutaneous Fat Volume-114.40 ± 54.88-155.20 ± 64.70-119.17 ± 113.11
Statistical analysis
  • CBL-514 480 mg · Paired t-test · p = <0.01 · Mean absolute fat volume difference: -114.40 · 95% CI -171.99 to -56.81
  • CBL-514 640 mg · Paired t-test · p = <0.01 · Mean absolute fat volume difference: -155.20 · 95% CI -223.10 to -87.30
  • CBL-514 800 mg · Paired t-test · p = <0.05 · Mean absolute fat volume difference: -119.17 · 95% CI -237.86 to -0.47

Adverse events

Collected over Up to 4 weeks after treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CBL-514 320 mg0/6 (0%)0/6 (0%)6/6 (100%)
CBL-514 480 mg0/7 (0%)0/7 (0%)7/7 (100%)
CBL-514 640 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
CBL-514 800 mg0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Closed head injury with post concussive symptomsInjury, poisoning and procedural complications0/60/71/60/6
Most frequent other events
Most frequent other events
EventCBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mg
Injection site erythemaGeneral disorders6/67/76/66/6
Injection site bruisingGeneral disorders6/66/76/66/6
Injection site painGeneral disorders6/66/76/66/6
Injection site swellingGeneral disorders6/66/76/66/6
Injection site pruritusGeneral disorders4/67/76/66/6
Injection site warmthGeneral disorders6/65/73/66/6
Injection site discolourationGeneral disorders6/66/73/61/6
Injection site indurationGeneral disorders6/64/72/64/6
PresyncopeNervous system disorders0/62/71/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Median52.5 (22 to 59)48 (19 to 56)31.5 (21 to 59)51.5 (33 to 61)51 (19 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Female656320
Male02035
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Hispanic or Latino00101
Not Hispanic or Latino675624
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
American Indian or Alaska Native00000
Asian02215
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White654419
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Australia676625
Body Mass Index
Body Mass Index(kg/m2)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Mean26.08 ± 1.9525.16 ± 2.5126.15 ± 3.7425.97 ± 2.6625.81 ± 2.64
Weight
Weight(kg)CBL-514 320 mgCBL-514 480 mgCBL-514 640 mgCBL-514 800 mgTotal
Mean69.46 ± 7.5875.25 ± 12.7065.93 ± 9.0175.48 ± 5.8071.68 ± 9.65
08

Study locations

1 site
  • Investigational Site
    Melbourne, Victoria, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Nov 2021, 11 months.

Results were first posted in Mar 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Oct 5, 2020
StartActual
Dec 9, 2020
Primary completionActual
Nov 15, 2021
CompletionActual
Dec 8, 2021
Results first posted
Mar 28, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04575467
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Dec 9, 2020
Primary completion
Nov 15, 2021
Completion
Dec 8, 2021
Results posted
Mar 28, 2024
Last update
Aug 9, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBL-514

Start the discussion